Please login to the form below

Not currently logged in
Email:
Password:

Key role for French cluster in regenerative medicine project

Medicen Paris Region will be responsible for long-term impact of the BONE project

regenerative medicineFrench life science cluster the Medicen Paris Region has been recruited to play a key role in a newly-launched European regenerative medicine project.

The four-year, €3.3m BONE project will see impacts developed using electrospinning - a procedure that uses electric charges to pull fibres from liquid.

These impacts, produced by Maastricht University in the Netherlands, have been tipped to become an alternative to repeat surgeries, prolonged medication use and donor tissue.

Medicen, a cluster of 300 life science organisations, will be responsible for activities relating to the dissemination and long-term impact of the project, as well as overall monitoring and matchmaking.

Béatrice Falise-Mirat, CEO of Medicen Paris Region, said: “Regenerative medicine is one of our five strategic activities; it is important to position each one at the European level.

“It’s a wonderful example of inter-cluster collaboration internationally and the added value that clusters can provide for European ecosystems.”

The initiative will unite Maastricht, Leuven and Lille universities along with the Fraunhofer Institute for Laser Technology ILT in Germany and technology firms based in the UK, Denmark and Ireland.

“We are thrilled that we are able to position the cluster and, more specifically the Ile-de-France region, in such an international context,” Falise-Mirat added.

The project - funded by the Interreg North-West Europe Program - has a total budget of €3.3m ($3.8m), and it is expected that the cluster will benefit from 15 new jobs, two new products and €162,000 ($185,000) in funding spread over the course of the project.

Article by
Gemma Jones

28th July 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford PharmaGenesis

Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...